Inflammation, coronary plaque progression, and statin use: A secondary analysis of the Risk Stratification with Image Guidance of HMG CoA Reductase Inhibitor Therapy (RIGHT) study

Background Statin treatment is a potent lipid‐lowering therapy associated with decreased cardiovascular risk and mortality. Recent studies including the PARADIGM trial have demonstrated the impact of statins on promoting calcified coronary plaque. Hypothesis The degree of systemic inflammation impac...

Full description

Saved in:
Bibliographic Details
Published in:Clinical cardiology (Mahwah, N.J.) N.J.), 2022-06, Vol.45 (6), p.622-628
Main Authors: Scott, Colin, Lateef, Sundus S., Hong, Christin G., Dey, Amit K., Manyak, Grigory A., Patel, Nidhi H., Zhou, Wunan, Sorokin, Alexander V., Abdelrahman, Khaled, Uceda, Domingo, Teklu, Meron, Wu, Colin, Parel, Philip M., Sandfort, Veit, Chen, Marcus Y., Mallek, Marissa, Ahlman, Mark, Bluemke, David, Mehta, Nehal N.
Format: Article
Language:English
Subjects:
Cardiac patients
Cardiovascular agents
Cardiovascular diseases
Clinical Investigations
coronary calcification
Development and progression
Health aspects
High density lipoprotein
Inflammation
Medical imaging
Mortality
statin treatment
Statins
Veins & arteries
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Statin treatment is a potent lipid‐lowering therapy associated with decreased cardiovascular risk and mortality. Recent studies including the PARADIGM trial have demonstrated the impact of statins on promoting calcified coronary plaque. Hypothesis The degree of systemic inflammation impacts the amount of increase in coronary plaque calcification over 2 years of statin treatment. Methods A subgroup of 142 participants was analyzed from the Risk Stratification with Image Guidance of HMG CoA Reductase Inhibitor Therapy (RIGHT) study (NCT01212900), who were on statin treatment and underwent cardiac computed tomography angiography (CCTA) at baseline and 2‐year follow‐up. This cohort was stratified by baseline median levels of high‐sensitivity hs‐CRP and analyzed with linear regressions using Stata‐17 (StataCorp). Results In the high versus low hs‐CRP group, patients with higher baseline median hs‐CRP had increased BMI (median [IQR]; 29 [27–31] vs. 27 [24–28]; p 
ISSN:0160-9289
1932-8737
DOI:10.1002/clc.23808